Literature DB >> 17380381

Clonality of lobular carcinoma in situ (LCIS) and metachronous invasive breast cancer.

Sebastian Aulmann1, Roland Penzel, Thomas Longerich, Benjamin Funke, Peter Schirmacher, Hans Peter Sinn.   

Abstract

Lobular carcinoma in situ (LCIS) of the breast is generally considered an indicator for a bilaterally increased risk of invasive breast cancer (IBC). However, as recent studies suggested a clonal relationship between a subset of synchronous LCIS and invasive lobular carcinomas (ILC), we aimed to examine a possible precursor role for LCIS and IBC occurring in the same breast at a later time. Out of a consecutive series of 88 LCIS, nine patients developed IBC (5 ILC and 4 invasive ductal carcinomas) between 2 and 10 years after initial biopsy. For each case, mitochondrial DNA heteroplasmy was analyzed in normal mammary gland epithelia, LCIS and IBC by PCR, direct DNA sequencing and phylogenetic tree clustering. Two cases of LCIS and ILC showed identical patterns of heteroplasmy. In one further case, additional mtDNA mutations were present in the ILC following LCIS. The remaining two cases of ILC and all 4 IDC were clonally unrelated to the previously diagnosed LCIS. While the overall risk for the development of invasive breast cancer following LCIS is relatively low and the majority of cases are clonally unrelated, our data clearly show that some LCIS eventually do progress to ILC. Thus, LCIS represents both an indicator lesion for an increased risk of subsequent invasive breast cancer and in some cases a precursor of ILC.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17380381     DOI: 10.1007/s10549-007-9557-0

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  17 in total

1.  Early Breast Cancer Precursor Lesions: Lessons Learned from Molecular and Clinical Studies.

Authors:  Hans-Peter Sinn; Zeinab Elsawaf; Birgit Helmchen; Sebastian Aulmann
Journal:  Breast Care (Basel)       Date:  2010-08-23       Impact factor: 2.860

2.  Breast cancer precursors: lessons learned from molecular genetics.

Authors:  Hans-Peter Sinn
Journal:  J Mol Med (Berl)       Date:  2009-01-13       Impact factor: 4.599

Review 3.  Current management of lesions associated with an increased risk of breast cancer.

Authors:  Monica Morrow; Stuart J Schnitt; Larry Norton
Journal:  Nat Rev Clin Oncol       Date:  2015-01-27       Impact factor: 66.675

4.  [Ductal and lobular preneoplasia: role in breast cancer development].

Authors:  S Aulmann
Journal:  Pathologe       Date:  2011-11       Impact factor: 1.011

5.  Cadherin-catenin complex dissociation in lobular neoplasia of the breast.

Authors:  Mary Morrogh; Victor P Andrade; Dilip Giri; Rita A Sakr; Wooyul Paik; Li Xuan Qin; Crispinita D Arroyo; Edi Brogi; Monica Morrow; Tari A King
Journal:  Breast Cancer Res Treat       Date:  2011-11-13       Impact factor: 4.872

6.  Gene expression profiling of lobular carcinoma in situ reveals candidate precursor genes for invasion.

Authors:  Victor P Andrade; Mary Morrogh; Li-Xuan Qin; Narciso Olvera; Dilip Giri; Shirin Muhsen; Rita A Sakr; Michail Schizas; Charlotte K Y Ng; Crispinita D Arroyo; Edi Brogi; Agnes Viale; Monica Morrow; Jorge S Reis-Filho; Tari A King
Journal:  Mol Oncol       Date:  2014-12-24       Impact factor: 6.603

Review 7.  [Lobular neoplasms and invasive lobular breast cancer].

Authors:  H-P Sinn; B Helmchen; J Heil; S Aulmann
Journal:  Pathologe       Date:  2014-02       Impact factor: 1.011

Review 8.  Lobular carcinoma in situ: diagnostic criteria and molecular correlates.

Authors:  Anna Sokolova; Sunil R Lakhani
Journal:  Mod Pathol       Date:  2020-10-06       Impact factor: 7.842

9.  [Clonal association of flat epithelial atypia and tubular breast cancer].

Authors:  S Aulmann; Z Elsawaf; R Penzel; P Schirmacher; H P Sinn
Journal:  Pathologe       Date:  2008-11       Impact factor: 1.011

Review 10.  Lobular Carcinoma In Situ.

Authors:  Hannah Y Wen; Edi Brogi
Journal:  Surg Pathol Clin       Date:  2017-12-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.